Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04336332 · ClinicalTrials.gov registry record · Phase 2
Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19
A Phase 2 study, sponsored by Rutgers, The State University of New Jersey.
- Terminated
- Registry status
- Phase 2
- Development phase
- 75
- Enrollment target
NCT04336332 is a Phase 2 study that was terminated before completion, run by Rutgers, The State University of New Jersey. The registered enrollment target is 75 participants.
The verdict
NCT04336332, a Phase 2 study, was terminated before completion, sponsored by Rutgers, The State University of New Jersey.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 75 participants
- Enrollment target
Study Summary
This is a three-arm randomized trial comparing the efficacy of single agent hydroxychloroquine to the combination of hydroxychloroquine and azithromycin, and to a delayed hydroxychloroquine regimen, which will serve as a contemporaneous Day 1-6 supportive care control, in eliminating detectable SARS-CoV-2 on day 6 following the initiation of treatment in order to determine which regimen is more effective.
Interventions
- DRUG Hydroxychloroquine Sulfate
- COMBINATION_PRODUCT Hydroxychloroquine Sulfate + Azithromycin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2020-04-01 |
| Est. Completion | 2020-10-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04336332
The ClinicalTrials.gov registry entry for NCT04336332 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 75 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Rutgers, The State University of New Jersey, which has 413 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Hydroxychloroquine Sulfate is the first listed.
NCT04336332 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04336332 about?
NCT04336332 is a clinical study titled "Randomized Comparison of Combination Azithromycin and Hydroxychloroquine vs. Hydroxychloroquine Alone for the Treatment of Confirmed COVID-19". This is a three-arm randomized trial comparing the efficacy of single agent hydroxychloroquine to the combination of hydroxychloroquine and azithromycin, and to a delayed hydroxychloroquine regimen, which will serve as a contemporaneous Day 1-6 supportive care control, in eliminating detectable SARS...
What is the current status of trial NCT04336332?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 75 participants. The study started on 2020-04-01. Estimated completion is 2020-10-14.
What interventions are being tested in trial NCT04336332?
The interventions under investigation include: Hydroxychloroquine Sulfate (DRUG), Hydroxychloroquine Sulfate + Azithromycin (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT04336332?
This trial is sponsored by Rutgers, The State University of New Jersey, which has 413 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.